The US Food & Drug Administration (FDA) has green-lighted dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease (COPD), Sanofi and Regeneron have announced, after a phase 3 trial programme showed a 30% to 34% reduction in moderate or severe exacerbations.
An injectable interleukin (IL)-4 and IL-13 pathway inhibitor, dupilumab is indicated as an add-on maintenance treatment for inadequately controlled COPD with an eosinophilic phenotype.
Medpage Today reports that primary support for the approval came from two phase 3 trials – BOREAS and NOTUSO – involving more than 900 COPD patients on maximal inhaled therapy (typically triple therapy) and with blood eosinophil evidence of type 2 inflammation.
Both studies met their primary endpoint, with dupilumab as a subcutaneous injection every two weeks reducing the annualised rate of moderate or severe COPD exacerbations versus placebo over a year.
In BOREAS, add-on treatment with dupilumab led to a 30% reduction in annual exacerbations (0.78 vs 1.10, respectively; rate ratio [RR] 0.70, 95% CI 0.58-0.86, P<0.001). And in NOTUS, dupilumab maintenance yielded a 34% reduction (0.86 vs 1.30; RR 0.66, 95% CI 0.54-0.82, P<0.001).
Trial data also showed improvements in quality of life and lung function, with numerically greater improvements in post-bronchodilator forced expiratory volume in 1 second (FEV1) and a significant improvement in pre-bronchodilator FEV1.
COPD causes progressive declines in lung function and consistently ranks in the top five leading causes of death in the US, where an estimated 300 000 adults with COPD have inadequately controlled disease and an eosinophilic phenotype.
“Sufferers have long awaited new medicines to help manage their daily experiences of breathlessness, coughing, wheezing, exhaustion, and unpredictable hospitalisation,” said Jean Wright, MD, CEO of the COPD Foundation.
“These patients often struggle with everyday activities many people take for granted, like simply taking a walk or running errands. We welcome the approval of this new therapeutic option that offers them a new way to help gain better control of their disease.”
The most common adverse events with dupilumab in BOREAS and NOTUS (>2%, and occurring more frequently than with placebo) included viral infection, headache, nasopharyngitis, back pain, diarrhoea, arthralgia, urinary tract infection, injection site reactions, rhinitis, eosinophilia, toothache, and gastritis.
Of note, cholecystitis was reported in more patients on dupilumab than placebo recipients (0.6% vs 0.1%).
Beyond COPD, dupilumab is also approved for atopic dermatitis , asthma, eosinophilic oesophagitis, chronic rhinosinusitis, and prurigo nodularis.
Medpage Today article – First-Ever Biologic Approved for COPD (Open access)
See more from MedicalBrief archives:
Drug trial shows promising results for COPD sufferers
Nearly half of women with asthma may develop COPD
Steroid inhalers in COPD management must be ‘carefully weighed’ — large study